Peter L Turecek

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Combination Therapy

Venous Thromboembolism

Infectious Diseases

Top Venues

Journal of blood medicine

Journal of thrombosis and haemostasis : JTH

Research and practice in thrombosis and haemostasis

This page only lists publications with an associated author ORCID identifier.

Publications

Zoran R Igrutinovic, Hélène Louise Hooimeijer, Karim Kentouche, Jaco Botha, Peter L Turecek, Marta Kokot-Kierepa, Hanna T Gazda
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B. Journal of blood medicine 15 (2024)
Zoran R Igrutinovic, Hélène Louise Hooimeijer, Karim Kentouche, Jaco Botha, Peter L Turecek, Marta Kokot-Kierepa, Hanna T Gazda
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B. Journal of blood medicine 15 (2024)
Peter L Turecek, Reinhard Ilk, Herbert Gritsch
In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products. Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Herbert Gritsch, Gerald Schrenk, Nina Weinhappl, Björn Mellgård, Bruce Ewenstein, Peter L Turecek
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Journal of blood medicine 13 (2022)
Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L Meeks, Jean-Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L Turecek, Nikola Tripkovic, Dargaud Yesim
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors. Research and practice in thrombosis and haemostasis 6 (4) (2022)
Peter L Turecek, Deborah Hibbett, Thomas R Kreil
Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry. Vox sanguinis 117 (6) (2022)
Jürgen Siekmann, Alfred Weber, Christoph Bauer, Peter L Turecek
Biochemical and cellular markers differentiate recovered, in-line filtered plasma, and plasma obtained by apheresis methods. Vox sanguinis (2021)
François Depasse, Nikolaus B Binder, Julia Mueller, Thomas Wissel, Stephan Schwers, Matthias Germer, Björn Hermes, Peter L Turecek
Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine. Journal of thrombosis and haemostasis : JTH 19 (12) (2021)
Nikolaus B Binder, François Depasse, Julia Mueller, Thomas Wissel, Stephan Schwers, Matthias Germer, Björn Hermes, Peter L Turecek
Clinical use of thrombin generation assays. Journal of thrombosis and haemostasis : JTH 19 (12) (2021)
Jürgen Siekmann, Alfred Weber, Christoph Bauer, Peter L Turecek
Reply to Farrugia: Appropriately specifying the quality of plasma for fractionation. Vox sanguinis (2021)
Reinhard Stidl, Michael Denne, Jimena Goldstine, Bill Kadish, Katherine I Korakas, Peter L Turecek
Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety. Pharmaceuticals (Basel, Switzerland) 11 (3) (2018)